UK parliamentary c'tee surveys Rx drug abuse

29 July 2007

The UK's All-Party Parliamentary Group on Drug Misuse has announced plans to investigate the extent of both prescription and over-the-counter drug abuse. Brian Iddon, the committee's chairman, told the UK's public service broadcaster, the BBC, that the aim of the study would be to identify the true scale and nature of the problem.

Dr Iddon said: "we know that thousands of people's lives have been affected by the misuse of drugs found in the home medicine cabinet or at the chemists." He added that the group was "also increasingly concerned about the number of users buying medicines on-line, where they face the very real risk of buying counterfeit products that may be dangerous."

As part of the investigation, the parliamentary group will invite the pharmaceutical industry, health care professionals and affected members of the public to give evidence. Reports from the US National Center on Alcohol and Substance Abuse indicate that, from 1993 to 2005, the use of tranquilizers such as Xanax (alprazolam) and Valium (diazepam) rose 450% among the student population, equivalent to an extra 225,000 people (Marketletter July 16).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight